Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) EBIT Margin (2016 - 2025)

Ironwood Pharmaceuticals (IRWD) has disclosed EBIT Margin for 16 consecutive years, with 161.38% as the latest value for Q4 2025.

  • Quarterly EBIT Margin fell 19616.0% to 161.38% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 4.97% through Dec 2025, down 2153.0% year-over-year, with the annual reading at 4.97% for FY2025, 2153.0% down from the prior year.
  • EBIT Margin hit 161.38% in Q4 2025 for Ironwood Pharmaceuticals, down from 61.84% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 63.03% in Q3 2022 to a low of 1008.68% in Q2 2023.
  • Historically, EBIT Margin has averaged 38.76% across 5 years, with a median of 34.98% in 2023.
  • Biggest five-year swings in EBIT Margin: crashed -106592bps in 2023 and later soared 103514bps in 2024.
  • Year by year, EBIT Margin stood at 114.0% in 2021, then fell by -6bps to 120.3% in 2022, then soared by 127bps to 31.98% in 2023, then rose by 9bps to 34.78% in 2024, then crashed by -564bps to 161.38% in 2025.
  • Business Quant data shows EBIT Margin for IRWD at 161.38% in Q4 2025, 61.84% in Q3 2025, and 53.17% in Q2 2025.